-
Abbott Laboratories’ Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment
•
US-based Abbott Laboratories (NYSE: ABT) has announced the receipt of the CE mark in the European Union (EU) for its Volt PFA System, a novel therapy for patients with atrial fibrillation (AFib). This approval marks a significant advancement in treatment options for AFib, particularly for those with complex conditions. Technology…
-
GSK and Abbott Announce Leadership Changes in Key Roles
•
Recent days have seen significant leadership changes at two pharmaceutical giants: UK-based GSK plc (LON: GSK) and US-based Abbott Laboratories (NYSE: ABT). GSK Appoints Jocelyn Luo as Mix Team LeaderJocelyn Luo has been appointed as the leader of GSK’s Mix team, reporting to Westly Yu, head of GSK’s respiratory business…
-
Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook
•
US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8% increase in organic sales to USD 10.974 billion. Excluding COVID-19 testing-related sales, the company achieved a 10.1% growth rate. For the full year, Abbott generated USD 42.0 billion in revenues, up 7.1% on an organic…
-
Henlius and Abbott Sign License Agreement for Biosimilars and Biologic Drug
•
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced a strategic license agreement with Abbott Laboratories (NYSE: ABT). The agreement grants the US multinational company exclusive or semi-exclusive development and commercialization rights to four biosimilars and one novel biologic drug in 69 emerging countries and regions. The deal, for which…
-
Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System
•
US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve implantation (TAVI) balloon-expandable system in treating the first patient with symptomatic severe aortic stenosis. This milestone marks a significant step forward in the company’s efforts to provide advanced heart valve therapies. Pioneering Software-Guided TAVI SystemThe…
-
Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility
•
Abbott Laboratories (NYSE: ABT), a leading US healthcare company, has announced the opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland. This new site, which serves as a global manufacturing center of excellence for Abbott’s diabetes care business, is expected to create over 800 new jobs. Details of the Kilkenny…
-
OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor
•
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution agreement with Cardiovascular Systems Inc. (CSI), a subsidiary of U.S. giant Abbott Laboratories (NYSE: ABT). Under this agreement, CSI will serve as the exclusive distributor of OrbusNeich’s coronary and peripheral balloon products in the United…
-
Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales
•
Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its financial results for the second quarter of 2024, highlighting a 9.3% year-on-year (YOY) increase in sales, reaching USD 10.4 billion in constant currency terms. The Medical Devices segment was the top performer, marking a 12.1%…
-
Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as the new Greater China Chief Commercial Officer (CCO), succeeding Liang Yi, who is departing from his role as both CCO and President of Greater China. Liang’s departure will become official on April 30. Zhu Tong’s…
-
Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices
•
Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for the first quarter of 2024. The company reported a 4.7% year-on-year (YOY) increase in global sales on an organic basis, reaching USD 10.0 billion. Excluding the impact of reduced demand for SARS-CoV-2 tests, the growth…
-
AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael
•
AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has been at the helm since the company’s separation from Abbott (NYSE: ABT) in 2013, will retire from his role as CEO. González will transition to the position of executive chairman of the board of directors,…
-
Abbott Reports Mixed 2023 Results with Q4 Growth Offsetting Full-Year Decline
•
US healthcare company Abbott (NYSE: ABT) has released its financial results for the fourth quarter and full year of 2023. The company’s Q4 global sales increased by 2.1% year-on-year (YOY) in constant currency terms to USD 10.24 billion, although for the full year, sales declined by 6.2% to USD 40.1…
-
Abbott Initiates Clinical Study for Volt PFA System in Australia for Cardiac Arrhythmias
•
Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt pulsed field ablation (PFA) system as part of a clinical study in Australia. The study is designed to evaluate the safety and effectiveness of the device in treating common cardiac arrhythmias such as atrial fibrillation…
-
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
•
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year (YOY) decline in global sales on an organic basis to USD 29.9 billion over the first three quarters. The decrease was primarily attributed to significantly reduced demand for SARS-CoV-2 tests, which led to a 42.1%…
-
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
•
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm mAbxience for select markets in Latin America, Southeast Asia, the Middle East, and Africa. mAbxience, which had its majority stake acquired by German group Fresenius (ETR: FRE) from Argentina-based Insud Pharma last year, specializes in…
-
Abbott to Acquire Insulin Management Firm Bigfoot Biomedical
•
Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company specializing in insulin management systems. The transaction is expected to be completed this month, subject to the fulfillment of customary conditions. Financial details of the acquisition were not disclosed. History of Collaboration and Continued PartnershipAbbott…
-
Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip
•
US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second quarter of 2023, reporting strong revenue and profit growth that exceeded analysts’ consensus. Despite a significant drop in sales of COVID-19 diagnostics from USD 2.3 billion a year ago to just USD 263 million in…
-
Abbott Partners with Sinopharm for Expanded Medical Solutions in China
•
US-based Abbott (NYSE: ABT) has entered into a strategic partnership with Sinopharm’s China National Medical Device Co., Ltd. The collaboration aims to leverage the respective strengths of both companies in technology, service network, and other areas to enhance the distribution of advanced medical technologies and solutions in China. Partnership Scope…
-
Abbott’s Q4 Sales Dip Amid COVID-19 Testing Decline, China Market Updates
•
US-based Abbott (NYSE: ABT) released its Q4 2022 financial results last week, showing a 6.1% year-on-year (YOY) decline in global sales to USD 10.091 billion, excluding foreign exchange impacts. Over the full year, sales increased 6.4% YOY to USD 43.65 billion. Abbott Chairman and CEO Robert B. Ford highlighted the…
-
CIIE: Bo’ao Lecheng Zone Announces Partnerships with Multinationals
•
The 5th China International Import Expo (CIIE) saw the Bo’ao Lecheng Medical Tourism Pilot Zone management bureau announce a series of strategic partnerships with multinational companies. These collaborations aim to enhance the zone’s capabilities in medical tourism and healthcare innovation. Partnership with Abbott LaboratoriesBoao Yiling and Abbott Laboratories’ diabetes department…
